FDA's rigid stance on rare disease drugs
The speaker argued the FDA is being overly dogmatic and inflexible in reviewing investigational drugs for rare diseases like Duchenne muscular dystrophy, denying patients access to potentially effective treatments.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.